Results 141 to 150 of about 31,062 (287)
ESC Heart Failure, EarlyView.The QUAD score was developed to promote adherence to clinical practice guidelines for patients with heart failure and a reduced left ventricular ejection fraction <50%. In newly diagnosed patients who had completed therapy titration, we found that patients with an excellent QUAD score had a significant reduction in the risk of mortality or ...
Henry Oluwasefunmi Savage +23 more
wiley +1 more source
Asymptomatic Left Ventricular Hypertrophy Is a Potent Risk Factor for the Development of HFpEF but Not HFrEF: Results of a Retrospective Cohort Study [PDF]
, 2022 А. Г. Овчинников +3 more
openalex +1 more source
ESC Heart Failure, EarlyView.Abstract In the 2021 European Society of Cardiology (ESC) heart failure (HF) guidelines, sodium–glucose cotransporter 2 (SGLT2) inhibitors were recommended for the prevention of HF in patients with type 2 diabetes mellitus (T2DM) and for the treatment of HF with reduced ejection fraction (HFrEF).
Marco Metra +25 more
wiley +1 more source
ESC Heart Failure, EarlyView.Abstract Aims Renal impairment frequently coexists with heart failure (HF) and is associated with increased risk of poor clinical outcomes. This highlights the urgent need for therapies targeting both cardiac and renal dysfunction. AZD3427, a long‐acting recombinant fusion protein and relaxin analogue that selectively activates the relaxin family ...
Marcin Ufnal +9 more
wiley +1 more source
ESC Heart Failure, EarlyView.Central Illustration caption: This analysis of vericiguat's treatment effect revealed no inter‐geographic region heterogeneity for the primary composite endpoint (time to HF‐related hospitalization or cardiovascular (CV) death or its components) (Left Panel).
Cynthia M. Westerhout +9 more
wiley +1 more source
ESC Heart Failure, EarlyView.Using EndoWings™ and XDROP™, we developed a percutaneous minimally invasive technique for sequential circumferential alginate hydrogel injection into LV free mid‐wall. This human study assessed its safety/feasibility in HFrEF patients, with personalised biomechanical models.
Bo Wang +13 more
wiley +1 more source
New pharmacological treatments for heart failure with reduced ejection fraction (HFrEF)
, 2020 Heng Li +7 more
openalex +1 more source
ESC Heart Failure, EarlyView.Abstract Aims Despite therapeutic advancements, the prognosis of heart failure (HF) remains poor, with high rates of mortality and readmission, particularly following a HF exacerbation. This study aimed to evaluate the effects of a nurse‐coordinated multidisciplinary comprehensive HF management programme on HF patients.
Cecilia Miu‐Ching Chan +13 more
wiley +1 more source
Soluble urokinase plasminogen activator receptor and outcomes in HFpEF: A TOPCAT ancillary study
ESC Heart Failure, EarlyView.Abstract Aims Inflammation is postulated to be a key pathogenic mechanism in heart failure with preserved ejection fraction (HFpEF). Soluble urokinase plasminogen activator receptor (suPAR), a regulator of innate immune activity, is associated with incident heart failure; however, its role in HFpEF remains unclear.
Christina G. Hutten +9 more
wiley +1 more source
ESC Heart Failure, EarlyView.Abstract Purpose Finerenone, a highly selective non‐steroidal mineralocorticoid receptor antagonist, was approved for the treatment of patients with chronic kidney disease (CKD) and type 2 diabetes mellitus (diabetic kidney disease, DKD). Finerenone reduced the composite endpoint of heart failure events and cardiovascular death in patients with heart ...
Kristian Hellenkamp +9 more
wiley +1 more source